EZH2 and neuroblastoma: demonstrated the possible mechanism of resistance to anti-GD2 therapy in NB in which the MES and the epigenetic rewiring to the ADRN state can control the levels of GD2 through the expression of ST8SIA1 (GD3S), an upstream GD2 catalytic enzyme, by the enhancer of zeste homolog 2 (EZH2)-dependent modulation.